How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "9501"
  ["article_id"]=>
  string(4) "9501"
  [1]=>
  string(64) "US approvals for updated COVID-19 vaccines targeting new variant"
  ["article_title"]=>
  string(64) "US approvals for updated COVID-19 vaccines targeting new variant"
  [2]=>
  string(119) "Updated versions of the leading vaccines for coronavirus have been approved by the US Food and Drug Administration.&#nl"
  ["short_description"]=>
  string(119) "Updated versions of the leading vaccines for coronavirus have been approved by the US Food and Drug Administration.&#nl"
  [3]=>
  string(119) "Updated versions of the leading vaccines for coronavirus have been approved by the US Food and Drug Administration.&#nl"
  ["description"]=>
  string(119) "Updated versions of the leading vaccines for coronavirus have been approved by the US Food and Drug Administration.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "81"
  ["rss_id"]=>
  string(2) "81"
  [14]=>
  string(110) "https://www.thepharmaletter.com/biotechnology/us-approvals-for-updated-covid-19-vaccines-targeting-new-variant"
  ["blog_url"]=>
  string(110) "https://www.thepharmaletter.com/biotechnology/us-approvals-for-updated-covid-19-vaccines-targeting-new-variant"
  [15]=>
  string(19) "2024-08-23 19:50:03"
  ["add_date"]=>
  string(19) "2024-08-23 19:50:03"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:25:17"
  ["create_at"]=>
  string(19) "2024-08-24 15:25:17"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

US approvals for updated COVID-19 vaccines targeting new variant

Updated versions of the leading vaccines for coronavirus have been approved by the US Food and Drug Administration.&#nl

array(40) {
  [0]=>
  string(4) "9386"
  ["article_id"]=>
  string(4) "9386"
  [1]=>
  string(62) "PCI Pharma Services’ Bedford completes ICMRA inspection"
  ["article_title"]=>
  string(62) "PCI Pharma Services’ Bedford completes ICMRA inspection"
  [2]=>
  string(150) "PCI Pharma Services (PCI), a global contract development and manufacturing organisation (CDMO), has completed the International Coalition of Medicines"
  ["short_description"]=>
  string(150) "PCI Pharma Services (PCI), a global contract development and manufacturing organisation (CDMO), has completed the International Coalition of Medicines"
  [3]=>
  string(230) "PCI Pharma Services (PCI), a global contract development and manufacturing organisation (CDMO), has completed the International Coalition of Medicines Regulatory Authorities (ICMRA) inspection of its Bedford, New Hampshire campus."
  ["description"]=>
  string(230) "PCI Pharma Services (PCI), a global contract development and manufacturing organisation (CDMO), has completed the International Coalition of Medicines Regulatory Authorities (ICMRA) inspection of its Bedford, New Hampshire campus."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(136) "https://www.medicalplasticsnews.com/news/medical-plastics-regulatory-policy-news/pci-pharma-services-bedford-completes-icmra-inspection/"
  ["blog_url"]=>
  string(136) "https://www.medicalplasticsnews.com/news/medical-plastics-regulatory-policy-news/pci-pharma-services-bedford-completes-icmra-inspection/"
  [15]=>
  string(19) "2024-08-23 19:30:00"
  ["add_date"]=>
  string(19) "2024-08-23 19:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:32"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:32"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

PCI Pharma Services’ Bedford completes ICMRA inspection

PCI Pharma Services (PCI), a global contract development and manufacturing organisation (CDMO), has completed the Intern

array(40) {
  [0]=>
  string(4) "9502"
  ["article_id"]=>
  string(4) "9502"
  [1]=>
  string(67) "Borealis Bio emerges from stealth with Versant and Novartis funding"
  ["article_title"]=>
  string(67) "Borealis Bio emerges from stealth with Versant and Novartis funding"
  [2]=>
  string(150) "Next-gen RNA-focused biotech Borealis Biosciences has emerged from stealth with $150 million in combined Series A financing from founding investor Ver"
  ["short_description"]=>
  string(150) "Next-gen RNA-focused biotech Borealis Biosciences has emerged from stealth with $150 million in combined Series A financing from founding investor Ver"
  [3]=>
  string(197) "Next-gen RNA-focused biotech Borealis Biosciences has emerged from stealth with $150 million in combined Series A financing from founding investor Versant Ventures and Swiss pharma giant Novartis. "
  ["description"]=>
  string(197) "Next-gen RNA-focused biotech Borealis Biosciences has emerged from stealth with $150 million in combined Series A financing from founding investor Versant Ventures and Swiss pharma giant Novartis. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "81"
  ["rss_id"]=>
  string(2) "81"
  [14]=>
  string(99) "https://www.thepharmaletter.com/borealis-bio-emerges-from-stealth-with-versant-and-vovartis-funding"
  ["blog_url"]=>
  string(99) "https://www.thepharmaletter.com/borealis-bio-emerges-from-stealth-with-versant-and-vovartis-funding"
  [15]=>
  string(19) "2024-08-23 19:14:24"
  ["add_date"]=>
  string(19) "2024-08-23 19:14:24"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:25:17"
  ["create_at"]=>
  string(19) "2024-08-24 15:25:17"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Borealis Bio emerges from stealth with Versant and Novartis funding

Next-gen RNA-focused biotech Borealis Biosciences has emerged from stealth with $150 million in combined Series A financ

array(40) {
  [0]=>
  string(4) "9503"
  ["article_id"]=>
  string(4) "9503"
  [1]=>
  string(75) "LEO Pharma’s Timber unit posts TMB-001 miss in congenital ichthyosis"
  ["article_title"]=>
  string(75) "LEO Pharma’s Timber unit posts TMB-001 miss in congenital ichthyosis"
  [2]=>
  string(155) "Danish dermatology specialist LEO Pharma’s Timber Pharmaceuticals subsidiary has announced disappointing results for the randomized, double-blind 12"
  ["short_description"]=>
  string(155) "Danish dermatology specialist LEO Pharma’s Timber Pharmaceuticals subsidiary has announced disappointing results for the randomized, double-blind 12"
  [3]=>
  string(189) "Danish dermatology specialist LEO Pharma’s Timber Pharmaceuticals subsidiary has announced disappointing results for the randomized, double-blind 12-week period of the ASCEND trial. "
  ["description"]=>
  string(189) "Danish dermatology specialist LEO Pharma’s Timber Pharmaceuticals subsidiary has announced disappointing results for the randomized, double-blind 12-week period of the ASCEND trial. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "81"
  ["rss_id"]=>
  string(2) "81"
  [14]=>
  string(99) "https://www.thepharmaletter.com/leo-pharmas-timber-unit-posts-tmb-001-miss-in-congenital-ichthyosis"
  ["blog_url"]=>
  string(99) "https://www.thepharmaletter.com/leo-pharmas-timber-unit-posts-tmb-001-miss-in-congenital-ichthyosis"
  [15]=>
  string(19) "2024-08-23 18:14:30"
  ["add_date"]=>
  string(19) "2024-08-23 18:14:30"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:25:17"
  ["create_at"]=>
  string(19) "2024-08-24 15:25:17"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

LEO Pharma’s Timber unit posts TMB-001 miss in congenital ichthyosis

Danish dermatology specialist LEO Pharma’s Timber Pharmaceuticals subsidiary has announced disappointing results 

array(40) {
  [0]=>
  string(4) "9351"
  ["article_id"]=>
  string(4) "9351"
  [1]=>
  string(75) "KFSHRC Empowers Future Healthcare Leaders with Innovative Research Programs"
  ["article_title"]=>
  string(75) "KFSHRC Empowers Future Healthcare Leaders with Innovative Research Programs"
  [2]=>
  string(75) "KFSHRC Empowers Future Healthcare Leaders with Innovative Research Programs"
  ["short_description"]=>
  string(75) "KFSHRC Empowers Future Healthcare Leaders with Innovative Research Programs"
  [3]=>
  string(75) "KFSHRC Empowers Future Healthcare Leaders with Innovative Research Programs"
  ["description"]=>
  string(75) "KFSHRC Empowers Future Healthcare Leaders with Innovative Research Programs"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(147) "https://www.globenewswire.com/news-release/2024/08/23/2934798/0/en/KFSHRC-Empowers-Future-Healthcare-Leaders-with-Innovative-Research-Programs.html"
  ["blog_url"]=>
  string(147) "https://www.globenewswire.com/news-release/2024/08/23/2934798/0/en/KFSHRC-Empowers-Future-Healthcare-Leaders-with-Innovative-Research-Programs.html"
  [15]=>
  string(19) "2024-08-23 17:46:00"
  ["add_date"]=>
  string(19) "2024-08-23 17:46:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:18"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

KFSHRC Empowers Future Healthcare Leaders with Innovative Research Programs

KFSHRC Empowers Future Healthcare Leaders with Innovative Research Programs

array(40) {
  [0]=>
  string(4) "9504"
  ["article_id"]=>
  string(4) "9504"
  [1]=>
  string(44) "Liquidia files suit challenging FDA decision"
  ["article_title"]=>
  string(44) "Liquidia files suit challenging FDA decision"
  [2]=>
  string(150) "Liquidia Corporation announced Thursday that it has filed litigation in the US District Court of the District of Columbia (Case No. 1:24-cv-02428) tha"
  ["short_description"]=>
  string(150) "Liquidia Corporation announced Thursday that it has filed litigation in the US District Court of the District of Columbia (Case No. 1:24-cv-02428) tha"
  [3]=>
  string(326) "Liquidia Corporation announced Thursday that it has filed litigation in the US District Court of the District of Columbia (Case No. 1:24-cv-02428) that challenges the recent decision by the US Food and Drug Administration (FDA) to grant three-year new clinical investigation (NCI) exclusivity to Tyvaso (treprostinil) DPI.9.6."
  ["description"]=>
  string(326) "Liquidia Corporation announced Thursday that it has filed litigation in the US District Court of the District of Columbia (Case No. 1:24-cv-02428) that challenges the recent decision by the US Food and Drug Administration (FDA) to grant three-year new clinical investigation (NCI) exclusivity to Tyvaso (treprostinil) DPI.9.6."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "81"
  ["rss_id"]=>
  string(2) "81"
  [14]=>
  string(76) "https://www.thepharmaletter.com/liquidia-files-suit-challenging-fda-decision"
  ["blog_url"]=>
  string(76) "https://www.thepharmaletter.com/liquidia-files-suit-challenging-fda-decision"
  [15]=>
  string(19) "2024-08-23 17:13:43"
  ["add_date"]=>
  string(19) "2024-08-23 17:13:43"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:25:18"
  ["create_at"]=>
  string(19) "2024-08-24 15:25:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Liquidia files suit challenging FDA decision

Liquidia Corporation announced Thursday that it has filed litigation in the US District Court of the District of Columbi

array(40) {
  [0]=>
  string(4) "9362"
  ["article_id"]=>
  string(4) "9362"
  [1]=>
  string(98) "SI-BONE To Present at Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024"
  ["article_title"]=>
  string(98) "SI-BONE To Present at Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024"
  [2]=>
  string(150) "SANTA CLARA, Calif., Aug.  22, 2024  (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disor"
  ["short_description"]=>
  string(150) "SANTA CLARA, Calif., Aug.  22, 2024  (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disor"
  [3]=>
  string(459) "
SANTA CLARA, Calif., Aug.  22, 2024  (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, September 4, 2024, at 10:45 a.m. Eastern Time / 7:45 a.m. Pacific Time.
"
  ["description"]=>
  string(459) "
SANTA CLARA, Calif., Aug.  22, 2024  (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, September 4, 2024, at 10:45 a.m. Eastern Time / 7:45 a.m. Pacific Time.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "27"
  ["rss_id"]=>
  string(2) "27"
  [14]=>
  string(169) "https://www.globenewswire.com/news-release/2024/08/22/2934608/0/en/SI-BONE-To-Present-at-Morgan-Stanley-22nd-Annual-Global-Healthcare-Conference-on-September-4-2024.html"
  ["blog_url"]=>
  string(169) "https://www.globenewswire.com/news-release/2024/08/22/2934608/0/en/SI-BONE-To-Present-at-Morgan-Stanley-22nd-Annual-Global-Healthcare-Conference-on-September-4-2024.html"
  [15]=>
  string(19) "2024-08-23 04:30:00"
  ["add_date"]=>
  string(19) "2024-08-23 04:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:22"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:22"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

SI-BONE To Present at Morgan Stanley 22nd Annual Global Healthcare Conference on September

SANTA CLARA, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medi

array(40) {
  [0]=>
  string(4) "9510"
  ["article_id"]=>
  string(4) "9510"
  [1]=>
  string(70) "Transitioning EU Clinical Trials:  Key Steps for Compliance by 2025"
  ["article_title"]=>
  string(70) "Transitioning EU Clinical Trials:  Key Steps for Compliance by 2025"
  [2]=>
  string(150) "To streamline processes, enhance transparency, and improve the overall efficiency of conducting clinical trials in the EU/EEA, the 3-year transition p"
  ["short_description"]=>
  string(150) "To streamline processes, enhance transparency, and improve the overall efficiency of conducting clinical trials in the EU/EEA, the 3-year transition p"
  [3]=>
  string(776) "
To streamline processes, enhance transparency, and improve the overall efficiency of conducting clinical trials in the EU/EEA, the 3-year transition period from the CTD to the CTR requirements was established. With the end of the transition period approaching, all ongoing clinical trials that were approved under the CTD will have to be fully be transitioned to comply with the CTR. Failure to comply by 2025 will bring serious consequences.
&#nl
The post Transitioning EU Clinical Trials:  Key Steps for Compliance by 2025 appeared first on MedTech Intelligence.
&#nl"
  ["description"]=>
  string(776) "
To streamline processes, enhance transparency, and improve the overall efficiency of conducting clinical trials in the EU/EEA, the 3-year transition period from the CTD to the CTR requirements was established. With the end of the transition period approaching, all ongoing clinical trials that were approved under the CTD will have to be fully be transitioned to comply with the CTR. Failure to comply by 2025 will bring serious consequences.
&#nl
The post Transitioning EU Clinical Trials:  Key Steps for Compliance by 2025 appeared first on MedTech Intelligence.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "98"
  ["rss_id"]=>
  string(2) "98"
  [14]=>
  string(114) "https://medtechintelligence.com/feature_article/transitioning-eu-clinical-trials-key-steps-for-compliance-by-2025/"
  ["blog_url"]=>
  string(114) "https://medtechintelligence.com/feature_article/transitioning-eu-clinical-trials-key-steps-for-compliance-by-2025/"
  [15]=>
  string(19) "2024-08-23 01:43:28"
  ["add_date"]=>
  string(19) "2024-08-23 01:43:28"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:26:32"
  ["create_at"]=>
  string(19) "2024-08-24 15:26:32"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Transitioning EU Clinical Trials: Key Steps for Compliance by 2025

To streamline processes, enhance transparency, and improve the overall efficiency of conducting clinical trials in th

array(40) {
  [0]=>
  string(4) "9511"
  ["article_id"]=>
  string(4) "9511"
  [1]=>
  string(69) "Transform Medical Device Logistics With Smart Packaging Strategies"
  ["article_title"]=>
  string(69) "Transform Medical Device Logistics With Smart Packaging Strategies"
  [2]=>
  string(153) "How does smart packaging improve medical device logistics operations? Learn about examples and explore how you might apply them. &#nlThe post Transform M"
  ["short_description"]=>
  string(153) "How does smart packaging improve medical device logistics operations? Learn about examples and explore how you might apply them. &#nlThe post Transform M"
  [3]=>
  string(463) "
How does smart packaging improve medical device logistics operations? Learn about examples and explore how you might apply them. 
&#nl
The post Transform Medical Device Logistics With Smart Packaging Strategies appeared first on MedTech Intelligence.
&#nl"
  ["description"]=>
  string(463) "
How does smart packaging improve medical device logistics operations? Learn about examples and explore how you might apply them. 
&#nl
The post Transform Medical Device Logistics With Smart Packaging Strategies appeared first on MedTech Intelligence.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "98"
  ["rss_id"]=>
  string(2) "98"
  [14]=>
  string(115) "https://medtechintelligence.com/feature_article/transform-medical-device-logistics-with-smart-packaging-strategies/"
  ["blog_url"]=>
  string(115) "https://medtechintelligence.com/feature_article/transform-medical-device-logistics-with-smart-packaging-strategies/"
  [15]=>
  string(19) "2024-08-23 01:38:17"
  ["add_date"]=>
  string(19) "2024-08-23 01:38:17"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:26:32"
  ["create_at"]=>
  string(19) "2024-08-24 15:26:32"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Transform Medical Device Logistics With Smart Packaging Strategies

How does smart packaging improve medical device logistics operations? Learn about examples and explore how you might 

array(40) {
  [0]=>
  string(4) "9323"
  ["article_id"]=>
  string(4) "9323"
  [1]=>
  string(60) "Battery Life Defect for Plum Infusion Systems Prompts Recall"
  ["article_title"]=>
  string(60) "Battery Life Defect for Plum Infusion Systems Prompts Recall"
  [2]=>
  string(153) "&#nl        ICU Medical is updating the use instructions for the Plum 360, Plum A+ and Plum A+3 Infusion Systems due to a manufacturing defect of the bat"
  ["short_description"]=>
  string(153) "&#nl        ICU Medical is updating the use instructions for the Plum 360, Plum A+ and Plum A+3 Infusion Systems due to a manufacturing defect of the bat"
  [3]=>
  string(261) "&#nl        ICU Medical is updating the use instructions for the Plum 360, Plum A+ and Plum A+3 Infusion Systems due to a manufacturing defect of the batteries, which can substantially diminish the life of the batteries and could put patients at risk.&#nl      "
  ["description"]=>
  string(261) "&#nl        ICU Medical is updating the use instructions for the Plum 360, Plum A+ and Plum A+3 Infusion Systems due to a manufacturing defect of the batteries, which can substantially diminish the life of the batteries and could put patients at risk.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(100) "https://www.fdanews.com/articles/214042-battery-life-defect-for-plum-infusion-systems-prompts-recall"
  ["blog_url"]=>
  string(100) "https://www.fdanews.com/articles/214042-battery-life-defect-for-plum-infusion-systems-prompts-recall"
  [15]=>
  string(19) "2024-08-22 23:40:19"
  ["add_date"]=>
  string(19) "2024-08-22 23:40:19"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:19:04"
  ["create_at"]=>
  string(19) "2024-08-24 15:19:04"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Battery Life Defect for Plum Infusion Systems Prompts Recall

&#nl ICU Medical is updating the use instructions for the Plum 360, Plum A+ and Plum A+3 Infusion Systems due to 

array(40) {
  [0]=>
  string(4) "9505"
  ["article_id"]=>
  string(4) "9505"
  [1]=>
  string(56) "NICE accepts Skyrizi for adults with ulcerative colitis "
  ["article_title"]=>
  string(56) "NICE accepts Skyrizi for adults with ulcerative colitis "
  [2]=>
  string(155) "US pharma major AbbVie today revealed that the UK’s National Institute for Health and Care Excellence (NICE) had accepted the firms Skyrizi (risanki"
  ["short_description"]=>
  string(155) "US pharma major AbbVie today revealed that the UK’s National Institute for Health and Care Excellence (NICE) had accepted the firms Skyrizi (risanki"
  [3]=>
  string(184) "US pharma major AbbVie today revealed that the UK’s National Institute for Health and Care Excellence (NICE) had accepted the firms Skyrizi (risankizumab) for adults with modera"
  ["description"]=>
  string(184) "US pharma major AbbVie today revealed that the UK’s National Institute for Health and Care Excellence (NICE) had accepted the firms Skyrizi (risankizumab) for adults with modera"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "81"
  ["rss_id"]=>
  string(2) "81"
  [14]=>
  string(87) "https://www.thepharmaletter.com/nice-accepts-skyrizi-for-adults-with-ulcerative-colitis"
  ["blog_url"]=>
  string(87) "https://www.thepharmaletter.com/nice-accepts-skyrizi-for-adults-with-ulcerative-colitis"
  [15]=>
  string(19) "2024-08-22 23:34:18"
  ["add_date"]=>
  string(19) "2024-08-22 23:34:18"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:25:18"
  ["create_at"]=>
  string(19) "2024-08-24 15:25:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

NICE accepts Skyrizi for adults with ulcerative colitis

US pharma major AbbVie today revealed that the UK’s National Institute for Health and Care Excellence (NICE) had 

array(40) {
  [0]=>
  string(4) "9428"
  ["article_id"]=>
  string(4) "9428"
  [1]=>
  string(68) "Vendors react to HHS' new proposed rule on health IT procurement"
  ["article_title"]=>
  string(68) "Vendors react to HHS' new proposed rule on health IT procurement"
  [2]=>
  string(150) "The proposal seeks to promote more effective use of healthcare technologies by ensuring they meet standards and implementation specs adopted by ASTP/O"
  ["short_description"]=>
  string(150) "The proposal seeks to promote more effective use of healthcare technologies by ensuring they meet standards and implementation specs adopted by ASTP/O"
  [3]=>
  string(157) "The proposal seeks to promote more effective use of healthcare technologies by ensuring they meet standards and implementation specs adopted by ASTP/ONC.&#nl"
  ["description"]=>
  string(157) "The proposal seeks to promote more effective use of healthcare technologies by ensuring they meet standards and implementation specs adopted by ASTP/ONC.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(95) "https://www.healthcareitnews.com/news/vendors-react-hhs-new-proposed-rule-health-it-procurement"
  ["blog_url"]=>
  string(95) "https://www.healthcareitnews.com/news/vendors-react-hhs-new-proposed-rule-health-it-procurement"
  [15]=>
  string(19) "2024-08-22 23:19:59"
  ["add_date"]=>
  string(19) "2024-08-22 23:19:59"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:43"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:43"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Vendors react to HHS' new proposed rule on health IT procurement

The proposal seeks to promote more effective use of healthcare technologies by ensuring they meet standards and implemen